Understood in one article! Chongqing International Biotech City pilot "exemption from environmental impact assessment" reduces the project implementation period by more than 3 months!
- Share
- Issue Time
- Apr 10,2025
Summary
At the forefront of the integration of biotechnology and industry, an industrial highland driven by reform and innovation is rising - Chongqing International Biotech City.
As one of the first pilot parks in China to optimize environmental impact assessment classification management, this area is reshaping the landing process of biopharmaceutical projects through the "exemption from environmental impact assessment" reform pilot.
At the same time, with strong innovation strength and industrial cluster advantages, it has become a core hub leading the development of the western bioeconomy.
1、 Policy innovation: The first pilot project in China to implement "exemption from environmental impact assessment" has been launched.
As one of the first pilot parks for optimizing environmental impact assessment classification management by the Ministry of Ecology and Environment, Chongqing International Biotech City will officially implement the "Pilot Implementation Plan for Optimizing Environmental Impact Assessment Classification Management Parks in Chongqing" in March 2025, leading the reform of "exemption from environmental impact assessment" for 10 categories of projects in the biopharmaceutical field nationwide.
What is the core of reform? For projects that meet environmental access requirements (ecological environment zoning control, park planning environmental impact assessment, industry standards) and do not exceed pollutant emissions standards, the approval of the environmental impact assessment report form is directly exempted, saving the tedious process of "acceptance publicity, technical review, and approval publicity".
Visualization of fermentation process! Understand AI+visualization, virtual reality+immersive experience, multimodal and multi-scale fusion
What effect has been achieved?
What are the successful landing cases?
Chongqing Tonggan Medical Technology Co., Ltd. HepAssis2 ® The bio artificial liver industrialization base project, as the first beneficiary project in the city, has a first phase investment of 200 million yuan and a production capacity of 12000 people per year. Relying on the "exemption from environmental impact assessment" policy, the project completed its application on the second day after the pilot plan was issued, shortening the conventional process by more than 3 months.
2、 Industrial highland: Breakthrough from "0" to "1", build a full chain ecosystem of biopharmaceuticals
Chongqing International Biotech City is the only national strategic emerging industry cluster and key biopharmaceutical industrial park in the city. It shoulders the mission of "1+5+N" pharmaceutical industry layout and "core park", and has formed a complete ecosystem from innovative drug research and development to achievement transformation.
On the one hand, innovative drug research and development leads the way in domestic substitution
In August 2024, Chongqing's first self-developed Class 1 innovative drug, Silimab Injection, was approved for market launch, breaking the monopoly of multinational pharmaceutical companies and achieving a breakthrough in Chongqing's innovative drug market from 0 to 1.
In 2025, the new indications for ankylosing spondylitis of Seriqi monoclonal antibody were approved.
At the same time, the world's first bispecific antibody for passive immunization of rabies, and the application for the marketing of type II diabetes drug, Lilalutide injection, were accepted by the State Food and Drug Administration, promoting the "successive" landing of innovative drug achievements.
On the other hand, the industrial cluster effect is prominent
The park focuses on 10 sub industries in three major fields: biopharmaceutical industry, medical equipment and device manufacturing, professional laboratories, and research and development (testing) bases.
It has gathered a number of leading enterprises and major projects, and the total output value will continue to rise from 2024 to 2025, accelerating its progress towards a biopharmaceutical characteristic industry cluster.
